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Abstract: Spathodea campanulata (P. Beauv.) Bignoniacea is widely used in Ugandan traditional medicine without 
having much knowledge on any toxicity data. This study carried out the toxicity profile of its methanolic stem bark 
extract (SCE) at both acute and sub-chronic levels. A single oral dose administration of SCE at the limit dose of 
study (5000 mg/kg) did not cause any observable toxic effect or mortality. However, a 90 day oral administration in 
Wistar rats (200, 400 and 800 mg/kg) resulted in an acceleration of bodyweight increase as indicated by the 
calculation of percentage bodyweight increments at the doses of study. It had no effect on the relative organ weights 
considered except an increase on the stomach at the 800 mg/kg dose. Among the biochemical parameters considered 
(ALT, AST ALP, GGT, creatinine and urea) the only significant (p<0.05) increase was observed with ALT at the 
800 mg/kg level. The levels of WBC, RBC, RDW and HCT dropped significantly (p<0.05) at the 800 mg/kg and 
400 mg/kg for WBC alone in the SCE-treated groups. There was however a significant elevation (p<0.05) of MCV, 
MCH, MCHC levels at 800 mg/kg in the treated animals compared to the control group. A histological analysis of 
the isolated organs (heart, testes, lungs, liver, stomach and kidneys) showed that the heart is the vulnerable organ 
with myocardial necrosis and hemorrhage occurring at the 400 and 800 mg/kg level following 90 days 
administration. Acute use of SCE is safe. Therefore, the resultant adverse effects observed on the lone liver enzyme 
(ALT) and the myocardial tissue at high doses following prolonged administration could be avoided if compliant use 
could be intermittent. 
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INTRODUCTION 
 
The use of herbal medicines is a worldwide 
confluence of traditional and alternative medical 
practices, as it is in almost all, if not all non orthodox 
medical systems be it Traditional African Medicine 
(TAM); Ayurveda, Siddha etc. in the Asian region; 
homoeopathy and other forms of Complementary/ 
Alternative Medicines in the Western world. Good 
enough the World Health Organisation estimated that 
about 80% of the population of the developing world 
depends primarily on herbal medicines for basic 
healthcare (WHO, 2003). Furthermore, there is 
increasing reliance on herbal medicines in the 
industrialised world which is traceable to the extraction 
and development of several drugs, chemotherapeutics 
from these plants as well as from traditionally used 
rural herbal remedies (UNESCO, 1998). The high level 
of dependence on the herbal medicines both in the rural 
communities and industrialised world is often backed 
by the belief that the use of orthodox drugs is 
synonymous with encountering deleterious effects 
which are absent in these herbal medicines. Some 
scientific data has pointed out to the fact that herbal 
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medicines are not without adverse effects and to add to 
it, revealed the realisation that there are possible 
interactions between contemporary drugs and herbal 
medicines that can produce deleterious effects. This 
erroneous impression is dangerously extended by 
parents and herbal treatment preferred for their children 
to conventional healthcare. There are too many 
instances where ignoring conventional treatment in 
favour of traditional medicine or CAM has ended up in 
regrettable consequences. It is noteworthy here that 
preference to CAM or traditional medicine is not 
usually only limited to mild conditions but also includes 
life-threatening conditions like cancer, diabetes, 
immunisation, HIV/AIDS etc. (Ernst, 2005). In the 
same write-up the author notes that some herbal 
preparations from India and China have been found to 
be contaminated with toxic heavy metals or strong 
prescription drugs and that puts the vulnerable children 
at particularly high risk of adverse effects and drug 
interactions. In the process of standardising herbal 
medicines it could be a laudable move if some effort is 
directed towards evaluating the safety of such before 
clinical use is authorised.  
Spathodea campanulata Bignoniacea (P.Beauv.) is 
a "Large tree with a stout, tapering often somewhat 
buttressed trunk, branches thickish, marked with small 
white lenticels, subglabrous to thinly puberulent, 
reaches heights of 25 m; leaves usually opposite (rarely 
3 at a node), very widely diverging, up to 50 cm long, 
dark green in colour. Spathodea campanulata invades 
both abandoned agricultural land and closed forest. It 
also invades natural ecosystems in the Cook Islands, 
Fiji, Guam, Hawaii, Samoa and Vanuatu. Although the 
African tulip tree favours moist and wet areas below 
1000 m it grows up to 1,200 m in French Polynesia. 
Spathodea campanulata does not tolerate frost and 
demands full sun for fast growth and best flowering. 
The biggest trees grow in moist sheltered ravines. This 
species loves rich soil, but puts up with just about 
anything with a little fertility to it, including lime rock. 
It will survive a bit of salinity. 
Spathodea campanulata invades agricultural areas, 
forest plantations and natural ecosystems, smothering 
other trees and crops as it grows becoming the 
prevailing tree in these areas. In Hawaii, there are major 
infestations tucked away in almost every rainforest 
valley along the northern and eastern slopes of Kaua'i, 
O'ahu and East Maui. In Uganda it is found in some 
rural homesteads as the boundary tree demarcating even 
grazing land. It is also found in the forests especially 
reserve areas in central and south western regions of the 
country.  
The seeds are edible. In Singapore the timber is 
used for making paper. In West Africa the wood is used 
to make drums and blacksmith's bellows. The bark, 
flowers and leaves are also used in traditional medicine 
in its native home range, (http://www.floridata.com/ 
ref/s/spat_cam.cfm). The wood is difficult to burn and 
so the tree can be used in fire resistant landscaping. 
Buds contain liquid that will squirt out if they are 
squeezed or pierced, which children enjoy using as 
water pistols. The use of this tree as a medicinal plant in 
Uganda has been reported by Hamill et al., 2003. The 
stem bark is extracted in banana beer (a local brew) and 
taken as treatment for diabetes. The water extract of the 
leaves is used as either an aphrodisiac for women or to 
improve on the production of vaginal fluid. Various 
medicinal uses have been described in different regions; 
in Rwanda it is used as an antidiabetic herbal remedy, 
(Niyonzima  et  al., 1999). While in Nigeria, (Makinde 
et al., 1988) and Cameroon, (Titanji et al., 2008) it is 
used to treat malaria, it is reported to have analgesic 
and anticonvulsant applications among Nigerian 
traditional healers as well as possessing reversible 
organ toxicity, (Ilodigwe and Akah, 2009). With such 
wide spread use of this plant further broadened by the 
multiplicity of the diseases it is used to treat in various 
regions, it is but necessary that the toxicity or safety 
profile of such a plant be established. Several studies 
have established toxicity of herbal medicines even with 
specialised toxicity patterns and on specific organs, 
(Kalplowitz, 1997; Calixto, 2000; Jaouad et al., 2004; 
Taziebou et al., 2007). In the same line besides 
developing guidelines for quality control of the 
processing of traditional medical remedies, the WHO 
encourages that traditional medical practices be 
incorporated in contemporary medical practices 
apparently in order to put under control the potential of 
adverse effects from herbal preparations. In a similar 
bid most research on medicinal plants routinely 
includes toxicity evaluation especially at the 
preliminary stages, (Balogun et al., 2011 and 
Ezeonwumelu et al., 2011). Ilodigwe et al. (2010) 
studied the toxicity of the leaf extract as it is used in 
Nigerian folk medicine. No toxicity study has been 
done on the stem bark relating to the pattern of its use 
in Ugandan traditional medicine. Hence, the basis for 
the study of the toxicity of this medicinal plant. The 
present investigations were aimed at evaluating the 
acute and sub-chronic toxicity profiles following oral 
administration of SCE to rats.  
 
MATERIALS AND METHODS 
 
Environmental considerations: Prior to beginning the 
collection of plant material in collaboration with the 
Rukararwe Traditional Healers Partnership (RTHP), 
two seedlings of Spathodea campanulata were obtained 
from the RTHP medicinal plants nursery and planted 
near the KIU-WC staff residential area. This was in 
compensation for any eventual adverse environmental 
consequences of collecting the medicinal plant material. 
The trees are presently mature.  
 
 
Br. J. Pharmacol. Toxicol., 
 
3 
Plant material collection and extraction: The stem 
bark of Spathodea campanulata was collected locally 
from Rukararwe Traditional Healers Partnership 
premises in Bushenyi, Uganda. Collection was done 
between 9:00 and 11:00 am in the month of May 2012. 
Authentication was done in the Department of Science 
Laboratory Technology of Mbarara University of 
Science and Technology by Dr. Eunice Olet and a 
voucher (JIBI JAMES 001) deposited in the herbarium 
of the same department. The stem bark was shade-
dried, powdered and taken for extraction. The plant 
material was extracted in 50% methanol using a soxhlet 
extractor (Quickfit) at the department of Pharmacology 
and Therapeutics of Mbarara University of Science and 
Technology. The crude extract was concentrated by 
distillation and further dried in an electrical oven 
(Mermmet®) at 40°C obtaining a yield of 40% w/w of 
plant material.  
 
Laboratory animal acquisition and maintenance: 
Healthy young adult Wistar rats (Rattus norvegicus) of 
both sexes weighing 100-150 g bred and maintained at 
the Laboratory Animal Facility of the Department of 
Pharmacology and Toxicology, Kampala International 
University-Western Campus were used according to the 
NIH guide for the Care and Use of Laboratory Animals 
in Teaching and Research (NIH Publication No. 83-27, 
1985). The animals were kept and maintained under 
ambient laboratory conditions of temperature, humidity, 
12 h light/12 h dark cycle. The animals were allowed 
access to standard rodent feed (Nuvita®, Jinja Uganda) 
and tap water ad libitum. Prior to the experiments the 
animals were fasted overnight while maintaining their 
free access to tap water. All animal studies were 
conducted after obtaining prior approval from Mbarara 
University of Science and Technology Institutional 
Review Committee (MUST-IRC; Ref: MUIRC 1/7) 
according to the Uganda National Council for Science 
and Technology (UNCST) guidelines for laboratory 
animal care and use. 
 
Acute toxicity evaluation: In order to carry out the 
acute toxicity evaluation of this SCE, the Organisation 
for Economic Cooperation and Development (OECD) 
guideline 425 of 2008 was adopted. The animals were 
deprived of food overnight prior to administration of 
the extract. In phase I, one male adult Wistar rat was 
administered 5,000 mg/kg SCE. The mouse was 
observed for signs of toxicity immediately and up to 24 
h after administration and scored for mortality. The 
probable signs observed for, were ataxia, diarrhoea, 
sedation, anorexia, increased activity, piloerection etc. 
In Phase II, two male young adult Wistar rats were 
treated as above. They were observed for signs of 
toxicity as in phase I above. Twenty-four hours later 
they were scored for mortality. The same procedure 
was repeated using male adult Wistar rats weighing 
100-150 g. The same animals were maintained under 
the usual laboratory conditions for two weeks and 
observed daily for any delayed toxic effects or 
mortality.  
 
Sub-chronic toxicity evaluation: The test was carried 
out according to the Organisation for Economic 
Cooperation and Development (OECD) test guidelines 
which describes long-term repeated dose toxicity 
testing, TG425 version (OECD, 2008). Twenty-four 
adult male Wistar rats were divided into four groups of 
six rats each (n = 6). Group I served as the control 
receiving as treatment distilled water. Groups I to IV 
received orally 200, 400 and 800 mg/kg bodyweight of 
SCE respectively and daily for 90 days. They were 
observed daily for two hours after administration for 
any clinical signs of toxicity like diarrhoea, sedation, 
anorexia, hyperactivity, dieresis, piloerection etc. The 
bodyweights of the animals were taken every seventh 
day beginning from the day of initiation of 
administration of SCE for the experimental groups and 
the distilled water for the control group. The percentage 
bodyweight increments were calculated every two 
weeks according to the following formula; percentage 
bodyweight increment = (bodyweight after two weeks-
initial bodyweight)/initial bodyweight x100. After the 
90th day the animals were sacrificed by cervical 
dislocation. Blood was collected by cardiac puncture 
and preserved in both EDTA and plain vacutainer® 
tubes for haematological and biochemical analysis 
respectively. All the vital organs were harvested and 
carefully weighed. The relative mean organ weights 
were determined using the formula: 
  
Relative mean organ weight = ﴾Mean organ weight 
(g)/mean body weight on last day (g)  ﴿ ×100% 
 
Haematological assays: The haematological 
parameters determined from the complete blood count 
include Red Blood Cell (RBC), haemoglobin (HGB), 
haematocrit (HCT), Mean Corpuscular Volume (MCV), 
Mean Corpuscular Haemoglobin (MCH), Red Cell 
Width (RDW), platelets (PLT) and Mean Platelet 
Volume (MPV) using a Beckman Coulter® Ac.T 
5DIFF CP. 
 
Biochemical assay: For the estimation of serum 
enzyme levels, the blood samples were allowed to 
coagulate for 30 min then centrifuged at 3,000 rpm for 
10 min and the clear serum was separated and used for 
the estimation of biochemical hepatic and renal serum 
parameters like alkaline phosphatise (ALP), aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), gamma glutamyltranspeptidase (GGT), 
creatinine kinase and urea using a HUMASTAR® 180 
automated chemistry analyzer. 
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Sample preparation for histopathology: The 
harvested organs were fixed in 10% saline formalin and 
preserved for histological studies. Histological 
examination was done on the preserved tissues (liver, 
kidney, lungs, heart, testes, stomach and intestines). 
The tissues were processed with microtome (Ernst Leitz 
Wetzler GMBH No. 537 Germany) and automated 
tissue processor, (USA). They were embedded in wax, 
sliced with the microtome and mounted on slides. The 
preparation was then stained with haematoxyline and 
eosin (Ganter and Jolles, 1970; Lucia et al., 2008). 
These tissues were then observed under a light 
microscope for possible histological changes and 
pictures taken with an eyepiece-attached digital camera 
(Sony Cybershot12.1pixels).  
 
Statistical analysis: The results are presented as 
means±SEM. Statistical significance between control 
and extract treated groups were determined using a one 
way Analysis of Variance (ANOVA) with the Dunnets 
post hoc test. A p-value <0.05 was considered 
statistically significant. 
  
RESULTS 
 
Acute toxicity study: Administration of SCE to both 
mice and rats by oral intubation at a dose of 5,000 
mg/kg did not cause any lethality. So the LD50 of the 
crude extract is high above the limit dose used in this 
study (5,000 mg/kg). During the two weeks post 
administration observation for probable delayed toxic 
effects, the animals (rats and mice) were seen to be 
normal as usual. No delayed toxic effects were 
observed. 
 
Sub-chronic toxicity:  
The effect of SCE on body weight: The general trend 
in the weight profile of the animals was that there was 
an increase in the bodyweights as seen in Table 1 
showing the mean bodyweights and the standard error 
of  the  mean.  Compared   to  the  control, there was no  
significant difference in the mean bodyweights 
(p<0.05) at the doses of SCE used. The calculated 
percentage increments on the mean bodyweight indicate 
that there was an overall increase in the percentage 
increment after every two weeks, that is, the percentage 
by which the bodyweight increased was higher after 
every two weeks, (Table 2). However, the percentage 
increment on the mean bodyweight of the animals 
started dropping at the sixth week. The end-result was 
an increase in the bodyweight increments or 
acceleration of bodyweight increase within the first four 
weeks.  
 
The effect of SCE on organ weight: The effect of SCE 
on organ weights was viewed in terms of its relativity to 
the final bodyweight, that is, the bodyweight on the 
sacrifice day (91st day). The percentages of the relative 
organ weights for the SCE-treated groups were similar 
and close in value for most of the considered organs; 
liver, kidneys, testes, lungs and heart relative to those of 
the control group. As for the stomach, the relative organ 
weight value was higher (2.67 and 2.97% respectively) 
for the 400 and 800 mg/kg of the SCE-treated groups 
compared  to  that  of  the control group (1.73%), 
(Table 3).  
 
The effect of SCE on biochemical parameters: With 
reference to Table 4, the following observations were 
made on the biochemical parameters considered; serum 
ALP, GGT and urea values for the SCE-treated groups 
were lower compared to the control. Serum AST, ALT 
and creatinine values were higher in the SCE-treated 
groups than in the control. However, the only 
statistically significant (p<0.05) increase was observed 
in serum ALT at the SCE 800 mg/kg level.  
 
The effect of SCE on haematological parameters: 
Significant changes (p<0.05) were observed in the 
haematological parameters. As can be seen on Table 5, 
while the levels of WBC, RBC, RDW and HCT 
dropped  significantly  (p<0.05)  at  the  800  mg/kg, the  
 
Table 1: Effect on Bodyweight Mean ± SEM n = 6 p≥0.05 
Treatment 
Dose 
(mg/kg) 
Bodyweight (g) on  
--------------------------------------------------------------------------------------------------------------------------------------------
Day 1 Day 14 Day 28 Day 42 Day 56 Day 70 Day 84 Day 91 
Control 10 mL/kg 104.0±4.1  127.0±4.8  162.6±4.7  174.8±7.9  190.9±5.5  191.6±4.3  210.6±4.8  210.7±5.5  
SCE  200 103.1±2.6 120.6±2.3 125.8±2.3 137.1±3.2 135.7±3.3 124.3±3.6 123.5±4.4 127.6±5.4 
SCE   400 101.5±6.9  122.5±6.9  149.5±6.6  158.8±7.2  175.5±7.5  185.6±8.4  196.4±9.3  204.1±8.4  
SCE   800 103.6±5.7  117.8±6.2  156.7±5.7  174.6±6.8  187.7±8.1  192.7±8.6  194.6±12.5  202.2±14.1 
 
Table 2: The effect of SCE on bodyweight increments in Rats 
Treatment group 
Percentage mean weight increments calculated every two weeks 
--------------------------------------------------------------------------------------------------------------------------------------------
14 28 42  56  70  84 91* 
Control 21.1 28.0 7.5  9.2  0.4  9.9 0.05 
SCE 200 mg/kg   11.4 3.0 6.4 -1.4 -6.1 -0.5 2.4 
SCE 400 mg/kg   20.7 22.7 6.2  10.5  5.8  5.8 3.9 
SCE 800 mg/kg   10.9  33.0 10.1  7.5  2.7  1 3.9 
*The day of sacrifice is not up to two weeks from the previous date 
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Table 3: Relative mean organ weight 
Treatment group 
Relative mean organ weight as a Percentage
--------------------------------------------------------------------------------------------------------------------------------------------
Liver Kidneys Testes Stomach Lungs Heart
Control 3.83 0.73 1.31 1.73 1.00 0.37
SCE 200mg/kg 3.20 0.73 1.30 1.35 1.07 0.37
SCE 400mg/kg 3.90 0.77 1.20 2.67 0.82 0.36
SCE 800mg/kg 4.01 0.78 1.30 2.97 0.99 0.36
 
Table 4: The effect of SCE on biochemical parameters  
Treatment group 
Biochemical parameters 
--------------------------------------------------------------------------------------------------------------------------------------------------
ALP U/I AST U/I ALT U/I GGT U/I CREATININE mg/dL UREA mg/dL
Control 944±210.5 28.3±8.4 62.8±18.1 109±43.3 0.71±0.15 119.8±16.5
SCE 200 mg/kg 506±187 385.3±137 192.4±32.6 66±22.9 0.66±0.8 58±8
SCE 400 mg/kg 602±124.2 472.7±212.7 245.5±73.8 124.2±56.7 0.91±0.21 99.3±24.9
SCE 800 mg/kg 763.3±153.1 586±279 365.7±111.8* 56.7±15.5 0.87±0.08 94.7±6.1
Values are Mean±SEM (n = 6); *value statistically significant at p<0.05 compared to the control 
 
Table 5: The effect of SCE on haematological parameters; (a) The Effect of SCE on Blood count 
Treatment WBC (x103/µL) RBC (x106/µL) RDW % PLT (x103/µL)
Control 5.4±0.34 8.3±0.23 11.3±0.29 321.7±74.3
SCE 200 mg/kg 5.64±0.67 8.29±0.28 11.54±0.25 275±70.8
SCE 400 mg/kg 3.2±0.6* 5.45±1.36 10±0.73 310±110.4
SCE 800 mg/kg 2.3±0.3* 3.34±1.14* 8.7±1.12* 53.83±20.32
WBC-White blood cell counts; RBC-Red blood cell counts; RDW-Red blood cell distribution; PLT-Platelet counts; Values are Mean±SEM (n = 
6); *values statistically significant at p<0.05 compared to the control 
 
Table 5: (b) The Effect of SCE on Hemoglobin Concentration and Mean Corpuscular value 
Treatment HGB g/dL HCT % MCV fl MCH pg MCHC g/dL MPV fl
Control 15.30±.50 43.60±1.48 52.00±0.52 18.32±0.23 35.10±0.24 8.20±1.10
SCE 200 mg/kg 15.16±0.58 43.20±1.76 51.80±0.58 18.26±0.27 35.08±0.30 8.62±1.18
SCE 400 mg/kg 14.50±0.77 30.37±5.9 66.60±9.16 47.40±17.9 62.22±16.49 7.40±0.36
SCE 800 mg/kg 13.3±1.36 20.37±4.44* 74.67±8.29* 65.33±15.11* 79.85±13.88*  11.13±1.89
HGB-Hemoglobin Concentration; HCT-Hematocrit values; MCV-Mean Corpuscular volume; MCH-Mean Corpuscular haemoglobin; MCHC-
Mean Corpuscular Haemoglobin Concentration; MPV-Mean Platelet Volume; Values are Mean±SEM (n = 6); *values statistically significant at 
p<0.05 compared to the control 
 
 
 
 
Br. J. Pharmacol. Toxicol., 
 
6 
 
 
Fig. 1a and b: a: Liver from experimental animal (SCE 800 mg/kg) showing vacoular degeneration of the hepatocytes; b: Liver 
normal (control animal) showing normal architectural arrangement of hepatocytes with normal looking 
hepatocytes 
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Fig. 2a and b: a: Heart from experimental animal, showing degeneration of myocardial cells which appeared more eosinophilic 
(arrow) than the normal cells; b: Heart, higher magnification of Fig. 2a, from experimental animal (SCE 800 
mg/kg)  showing degeneration of  myocardial cells 
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Fig. 3a and b: a: Lung from control animal. Not the normal thin interalveolar septae; b: Lung from experimental animal (SCE 
800 mg/kg) with thickening of the interalveolar septae 
 
 
 
Fig. 4: Lung from experimental animal (SCE 800 mg/kg) showing pulmonary parenchymal haemorrhage 
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WBC value alone behaved in the same manner at 400 
mg/kg in the SCE-treated groups. There was however a 
significant elevation (p<0.05) of MCV, MCH, MCHC 
levels at 800 mg/kg in the treated animals compared to 
the control group. 
 
The effect of SCE on tissues: Light microscopic 
examination of different organs showed some tissue 
lesions due to the effects of the extract (SCE). 
Microscopic examination of the liver revealed vacuolar 
degeneration (Fig. 1b). Lesions of the heart of the 
animals treated with 400 and 800 mg/kg bodyweight of 
SCE indicated wide spread degeneration of individual 
myocardial cells with focal areas of myocardial 
necrosis (Fig. 2a and b). Focal areas of myocardial, 
epicardial and subepicardial hemorrhages were 
observed. Mild mononuclear cell infiltration was 
mostly common with the 800 mg/kg SCE-treated group. 
The lung of animals treated with 400 mg/kg SCE 
commonly indicated thickening of the inter-alveolar 
septae as well as marked parenchymal hemorrhage (Fig. 
3b and 4). Hyperplasia of peribronchial lymphoid 
tissue, perivascular infiltration with mononuclear cells 
and pulmonary edema were occasionally observed. 
Lung from the 800 mg/kg SCE-treated animals showed 
similar effects but with more frequent occurrences of 
alveolar emphysema and perivascular infiltration with 
mononuclear cells. The sections of the testes of the rats 
treated with both 400 and 800 mg/kg SCE were 
observed to show mild interstitial edema. The sections 
of the stomach examined included the glandular portion 
and the cornified squamous portion. The glandular 
mucosae of the SCE-treated rats were vacuolated. 
Sections of the kidney showed mild to moderate 
degeneration of the tubular epithelial cells at the doses 
400 and 800 mg/kg of SCE.  
  
DISCUSSION 
 
Acute toxicity studies of SCE in both mice and rats 
indicated that the LD50 value of the extract is high 
above 5,000 mg/kg bodyweight. This implies that the 
said extract is sufficiently safe for single-dose use as it 
is applied in traditional medicine in Uganda for the 
treatment of diabetes mellitus and other ailments, 
(Hamill et al., 2003). The use of some medicinal plants 
in traditional medicines in various parts of the world 
has been established to be safe as well, (Ogwal-Okeng 
et al., 2003; Balogun  et  al.,  2011  and  Ezeonwumelu 
et al., 2012). This safety profile following single dose 
administration should however not be mistaken for that 
following chronic use. There is a need to investigate the 
likely toxic effect of long term use as is the case with 
compliant treatment of diabetes mellitus, which 
treatment is a lifetime process.  
The SCE consumption by rats for a period of 90 
days did not influence the increase in body weight. 
Comparing the treated groups to the control the gain in 
body weight did not have any significant difference 
(p<0.05) in the increase. The increase in body weight 
experienced by the animals was a normal growth 
process owing to the fact that the experiment was 
started with growing young adult rats. Unlike other 
traditional herbal portions which have been found to 
cause bodyweight loss (Ezeonwumelu et al., 2011), 
SCE does not cause it. Traditional use may not be 
associated with weight reduction as side effects that can 
complicate its use. There is similarly, no significance in 
the drop of the increments of the percentage weight 
increments that was observed singly in the SCE 200 
mg/kg treated group given that all the increments 
decline after the sixth week of the experiment. This 
parameter does not signify any deterrent in bodyweight 
increase since it is neither severe nor dose-dependent. 
Bodyweight loss could be caused through such 
mechanisms as loss of appetite, malabsorption or the 
presence of anti-nutritional elements, (Ilodigwe et al., 
2010) and advanced age. Increased (organomegaly) or 
decreased (atrophy) organ weight (relative or absolute) 
has been noted as a sensitive indicator of adverse effect 
on organs caused by standard toxicants, (Dioka et al., 
2002). The relative organ weights expressed as a 
percentage mostly appeared similar to the control 
values though the stomach values appeared higher at 
the 400 and 800 mg/kg dose that leaves a lot to be 
desired in the tendency for causing organomegaly at the 
level of the stomach. Histological analysis may have to 
be considered to conclude the existence of such 
pathology.  
The considered biochemical parameters ALP, 
GGT, AST, creatinine and urea that did not show any 
statistically significant difference (p<0.05) indicate that 
the effect of SCE treatment may not appreciably 
negatively influence hepatic function as well as the 
renal elimination process. This fact varies with the 
observation of Ilodigwe et al., 2010 on the ethanolic 
extract of the leaves of Spathodea campanulata. 
Creatinine and urea are the chosen parameters that give 
an estimate of renal capacity to eliminate some 
metabolites. Non significant rise in ALP and GGT 
levels precisely indicates the non existence of 
cholestatic liver disease at the doses studied since high 
ALP  levels  are  characteristic  of  cholestasis, (Aniagu 
et al., 2005). The ALT level that is significantly higher 
(p<0.05) than the control at 800 mg/kg level is one of 
the key liver aminotransferases and a reliable indicator 
of specific liver congestion or injury. Some plant 
extracts are observed to cause liver damage in a similar 
manner but the liver is such a readily regenerating 
organ that more often the hepatotoxicity may be 
reversible after some time following discontinuation of 
the use of the causative agent, (Ilodigwe et al., 2010). It 
should also be borne in mind that whether 
hepatotoxicity is temporal or long lasting will depend 
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on the type of phytochemicals present in the plant 
material or if it were contaminated by other hapatotoxic 
organic agents like afflatoxins.  
Changes in haematological parameters have been 
noted as an important indicator of toxicity of medicinal 
plants just like other haematotoxic agents, (Dioka et al., 
2002). The significant drop noticed in the values of 
haematological components such as WBC, RBC, RDW 
and HCT at 800 mg/kg and WBC alone at 400 mg/kg 
gives an indication that prolonged use of SCE may 
cause appreciable anaemia especially at high doses 
though curiously enough there was no statistically 
significant difference in the value of haemoglobin 
(HGB). A severe drop in the values of MCV, MCH and 
MCHC levels occurs in the condition of thallasaemia. 
The significant rise in MCV, MCH, MCHC levels at 
800 mg/kg body weight in the treated animals 
compared to the control group are indicative of the fact 
that this extract may instead cause a reversal of the 
signs of thallasaemia which is an added advantage that 
may be exploited for therapeutic use.  
Organ tissue damage is considered as an important 
target for xenobiotic toxicity, (Klaassen and Watkins, 
2010). Organ effects resulting from exposure to 
xenobiotics occurs as lesions of varying category 
depending on the duration, concentration, route of 
exposure, potency among other factors. Most of the 
organs examined after the 90 days administration of 
SCE did not show signs of severe or permanent injury. 
The effects on the kidney, stomach, testes, lungs and 
liver were mild to moderate lesions which could be 
repaired following discontinuation of the SCE 
administration. The tissues could recover from such 
injury. However, the heart seemed to be more 
vulnerable to the administration of SCE considering the 
wide spread distribution and degree of the lesions 
observed on the myocardium. The observed myocardial 
necrosis with haemorrhage at the doses 400 and 800 
mg/kg is an irreversible lesion that may have long 
lasting and devastating cardiac defects.  
 
CONCLUSION 
 
SCE is practically safe when used as a single dose 
treatment. Prolonged use of this extract may not have 
any influence on bodyweight but may cause an increase 
in stomach weight and injurious lesion on the 
myocardium. Prolonged use of this extract may also 
cause haematological and hepatological injury. 
However, these observed injuries may be avoided by 
intermittent use and could eventually be reversed by 
discontinuation.  
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